Zika virus has an oncolytic activity against human glioblastoma U87 cells

Svyatchenko, V. A.; Разумов, И. А.; Протопопова, Е. В.; Демина, А. В.; Solovieva, Olga I.; Zavjalov, Evgenii L.; Loktev, V. B.

doi:10.18699/vj18.448

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, most studies on polio vaccine virus in Russia have been limited to rat glioma [59,60] with the exception of [23]. The Zika virus, a representative of flaviviruses, has recently attracted particular interest, since it exhibits a significant selectivity towards glioblastoma stem cells [61,62].…”

Section: Ovs In Glioblastoma Treatmentmentioning

confidence: 99%

Oncolytic Viruses in Tumor Therapy: The Russian Perspective

Nm¹,

Pestov²,

Jm³

et al. 2021

Preprint

View full text Add to dashboard Cite

The idea of using the lytic power of viruses against the malignant cells has been entertained for many decades. However, oncolytic viruses (OV) gained broad attention as an emerging anti-cancer therapy only recently with the successful implementation of the oncolytic herpesvirus to treat advanced melanoma. OVs offer an attractive therapeutic combination of tumor-specific cell lysis together with immune stimulation, yet the latter effect is less well studied. Nevertheless, OVs can be envisaged as potential in situ tumor vaccines. The therapeutic potential of OVs can be instigated further by using the molecular biological and biotechnological tools to modify the existing viruses for their optimal tumor selectivity and enhanced immune stimulation. Furthermore, OVs can be readily combined with other therapeutic agents to increase the efficacy of the existing therapeutic schemes. In this review, we discuss biotechnological advances in the development of therapeutic applications of OVs in Russia. Particular emphasis is made on the OV-mediated treatment of glioblastoma. In addition, we highlight the challenges of oncolytic virotherapy, and describe the strategies to optimize current approaches to improve clinical outcomes.

show abstract

Section: Ovs In Glioblastoma Treatmentmentioning

confidence: 99%

Oncolytic Viruses in Tumor Therapy: The Russian Perspective

Nm¹,

Pestov²,

Jm³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future

Kolyasnikova

Pestov

Sanchez-Pimentel

et al. 2023

CPB

View full text Add to dashboard Cite

The idea of using the lytic power of viruses against malignant cells has been entertained for many decades. However, oncolytic viruses gained broad attention as an emerging anti-cancer therapy only recently with the successful implementation of several oncolytic viruses to treat advanced melanoma. Here we review the history of oncolytic viruses in the Russian Federation and recent biotechnological advances in connection with the perspectives of their practical use against aggressive tumors such as glioblastoma or pancreatic cancer. A particular emphasis is made on novel applications of safe non-lytic virus-derived vectors armed with prodrug-converting enzyme transgenes. Rational improvement of oncotropism by conjugation with biopolymers and nanoformulations is also discussed.

show abstract

Investigation of oncolytic potential of vaccine strains of yellow fever and tick-borne encephalitis viruses against glioblastoma and pancreatic carcinoma cell lines

Nazarenko,

Biryukova,

Orlova

et al. 2023

Problems of Virology

View full text Add to dashboard Cite

Introduction. Flaviviruses, possessing natural neurotropicity could be used in glioblastoma therapy using attenuated strains or as a delivery system for antitumor agents in an inactivated form. Objective. To investigate the sensitivity of glioblastoma and pancreatic carcinoma cell lines to vaccine strains of yellow fever and tick-borne encephalitis viruses. Materials and methods. Cell lines: glioblastoma GL-6, T98G, LN-229, pancreatic carcinoma MIA RaCa-2 and human pancreatic ductal carcinoma PANC-1. Viral strains: 17D yellow fever virus (YF), Sofjin tick-borne encephalitis virus (TBEV). Virus concentration were determined by plaque assay and quantitative PCR. Determination of cell sensitivity to viruses by MTT assay. Results. 17D YF was effective only against pancreatic carcinoma tumor cells MIA Paca-2 and had a limited effect against PANC-1. In glioblastoma cell lines (LN229, GL6, T98G), virus had no oncolytic effect and the viral RNA concentration fell in the culture medium. Sofjin TBEV showed CPE50 against MIA Paca-2 and a very limited cytotoxic effect against PANC-1. However, it had no oncolytic effect against glioblastoma cell lines (LN229, T98G and GL6), although virus reproduction continued in these cultures. For the GL6 glioblastoma cell line, the viral RNA concentration at the level with the infection dose was determined within 13 days, despite medium replacement, while in the case of the LN229 cell line, the virus concentration increased from 1 × 109 to 1 × 1010 copies/ml. Conclusion. Tumor behavior in organism is more complex and is determined by different microenvironmental factors and immune status. In the future, it is advisable to continue studying the antitumor oncolytic and immunomodulatory effects of viral strains 17D YF and Sofjin TBEV using in vivo models.

show abstract

Zika virus has an oncolytic activity against human glioblastoma U87 cells

Cited by 3 publications

References 24 publications

Oncolytic Viruses in Tumor Therapy: The Russian Perspective

Oncolytic Viruses in Tumor Therapy: The Russian Perspective

Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future

Investigation of oncolytic potential of vaccine strains of yellow fever and tick-borne encephalitis viruses against glioblastoma and pancreatic carcinoma cell lines

Contact Info

Product

Resources

About